Anticancer activity and mechanism of Scutellaria barbata extract on human lung cancer cell line A549

被引:198
作者
Yin, XL
Zhou, JB
Jie, CF
Xing, DM
Zhang, Y
机构
[1] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA
[3] Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China
关键词
cancer; herbal medicine; Scutellaria barbata;
D O I
10.1016/j.lfs.2004.05.015
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Scutellaria barbata (S. barbata), a traditional Chinese herbal medicine native to southern China, is widely used as an anti-inflammatory and a diuretic in China. Several studies have indicated that extracts of S. barbata have growth inhibitory effects on a number of human cancers. Treatment of lung cancer, digestive system cancers, hepatoma, breast cancer, and chorioepithelioma by S. barbata extracts was reported. However, the mechanism underlying the antitumor activity was unclear. In this study, we studied the growth inhibitory effect of S. barbata and determined its mechanism of antitumor activity using human lung cancer cell line A549. Our results showed that ethanol extracts of S. barbata greatly inhibited A549 cell growth, with IC50 of 0.21 mg/ml. The major mechanisms of inhibition included cell apoptosis and cytotoxic effects. cDNA microarray analysis showed that 16 genes, involved in DNA damage, cell cycle control, nucleic acid binding and protein phosphorylation, underwent more than 5-fold change. These data indicated that these processes are involved in S. barbata-mediated killing of cancer cells. A surprising finding is that CD209, related to dendritic cell (DC) function, was dramatically downregulated by 102-fold. Further functional studies are needed to assess the role of the array-identified genes in S. barbata mediated anticancer activity. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:2233 / 2244
页数:12
相关论文
共 27 条
[1]  
ALBERTI W, 1995, BRIT MED J, V311, P899
[2]  
Bedner E, 1999, CYTOMETRY, V35, P181, DOI 10.1002/(SICI)1097-0320(19990301)35:3<181::AID-CYTO1>3.0.CO
[3]  
2-5
[4]   Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an eastern cooperative oncology group trial [J].
Bonomi, P ;
Kim, KM ;
Fairclough, D ;
Cella, D ;
Kugler, J ;
Rowinsky, E ;
Jiroutek, M ;
Johnson, D .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) :623-631
[5]   Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer [J].
Cardenal, F ;
López-Cabrerizo, MP ;
Antón, A ;
Alberola, V ;
Massuti, B ;
Carrato, A ;
Barneto, I ;
Lomas, M ;
García, M ;
Lianes, P ;
Montalar, J ;
Vadell, C ;
González-Larriba, JL ;
Nguyen, B ;
Artal, A ;
Rosell, R .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :12-18
[6]  
Chou G., 2003, BIOCHEM PHARMACOL, V66, P115
[7]   Caspases: the executioners of apoptosis [J].
Cohen, GM .
BIOCHEMICAL JOURNAL, 1997, 326 :1-16
[8]   Trends in alternative medicine use in the United States, 1990-1997 - Results of a follow-up national survey [J].
Eisenberg, DM ;
Davis, RB ;
Ettner, SL ;
Appel, S ;
Wilkey, S ;
van Rompay, M ;
Kessler, RC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (18) :1569-1575
[9]  
Huang K.C., 1999, PHARM CHINESE HERBS
[10]   Superoxide dismutase as a target for the selective killing of cancer cells [J].
Huang, P ;
Feng, L ;
Oldham, EA ;
Keating, MJ ;
Plunkett, W .
NATURE, 2000, 407 (6802) :390-395